Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Recordati Industria Chimica e Farmaceutica Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Recordati Industria Chimica e Farmaceutica wird ein jährliches Gewinn- und Umsatzwachstum von 10.4% bzw. 5.7% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 36.7% betragen.
Wichtige Informationen
10.4%
Wachstumsrate der Gewinne
10.1%
EPS-Wachstumsrate
| Pharmaceuticals Gewinnwachstum | 14.2% |
| Wachstumsrate der Einnahmen | 5.7% |
| Zukünftige Eigenkapitalrendite | 36.7% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 13 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
May 26
Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.63
May 10Recordati Industria Chimica e Farmaceutica's (BIT:REC) Dividend Will Be Increased To €0.63
Apr 25Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Share Price Could Signal Some Risk
Apr 23If EPS Growth Is Important To You, Recordati Industria Chimica e Farmaceutica (BIT:REC) Presents An Opportunity
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.63
Mar 23Is Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 27We Think Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Stay On Top Of Its Debt
Jan 09Risks To Shareholder Returns Are Elevated At These Prices For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.57
Nov 12Is Recordati Industria Chimica e Farmaceutica (BIT:REC) Using Too Much Debt?
Sep 29Estimating The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 08Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 23Does This Valuation Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Imply Investors Are Overpaying?
Jun 05Recordati Industria Chimica e Farmaceutica's (BIT:REC) Conservative Accounting Might Explain Soft Earnings
Apr 08Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.60
Apr 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Has Announced That It Will Be Increasing Its Dividend To €0.60
Mar 19Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Mar 06A Look At The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Dec 05Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.55
Nov 11Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Intrinsic Value Is Potentially 42% Above Its Share Price
Sep 01These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Aug 07An Intrinsic Calculation For Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Suggests It's 25% Undervalued
Jun 03Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 16Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Paying Out A Larger Dividend Than Last Year
May 02Recordati Industria Chimica e Farmaceutica's (BIT:REC) Shareholders Will Receive A Bigger Dividend Than Last Year
Apr 18Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Increasing Its Dividend To €0.57
Apr 04Recordati Industria Chimica e Farmaceutica (BIT:REC) Will Pay A Larger Dividend Than Last Year At €0.57
Mar 21These 4 Measures Indicate That Recordati Industria Chimica e Farmaceutica (BIT:REC) Is Using Debt Reasonably Well
Mar 06Calculating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Dec 22Recordati Industria Chimica e Farmaceutica (BIT:REC) Has A Pretty Healthy Balance Sheet
Dec 05Estimating The Intrinsic Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Sep 23Is Recordati Industria Chimica e Farmaceutica (BIT:REC) A Risky Investment?
Sep 05A Look At The Fair Value Of Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Jun 25Here's Why Recordati Industria Chimica e Farmaceutica (BIT:REC) Can Manage Its Debt Responsibly
Jun 07Earnings Miss: Recordati Industria Chimica e Farmaceutica S.p.A. Missed EPS By 8.5% And Analysts Are Revising Their Forecasts
May 10Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC) Shares Could Be 34% Above Their Intrinsic Value Estimate
Mar 11Here's What You Should Know About Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) 2.4% Dividend Yield
Feb 19Recordati Industria Chimica e Farmaceutica S.p.A.'s (BIT:REC) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jan 30Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 2,556 | 556 | 611 | 703 | 6 |
| 12/31/2025 | 2,440 | 524 | 538 | 661 | 8 |
| 12/31/2024 | 2,301 | 478 | 488 | 634 | 9 |
| 3/31/2024 | 2,139 | 389 | 154 | 528 | N/A |
| 12/31/2023 | 2,082 | 389 | 102 | 485 | N/A |
| 9/30/2023 | 2,032 | 375 | 134 | 510 | N/A |
| 6/30/2023 | 2,005 | 389 | 438 | 507 | N/A |
| 3/31/2023 | 1,985 | 340 | 360 | 456 | N/A |
| 12/31/2022 | 1,853 | 312 | 367 | 462 | N/A |
| 9/30/2022 | 1,801 | 331 | 391 | 485 | N/A |
| 6/30/2022 | 1,702 | 330 | 422 | 504 | N/A |
| 3/31/2022 | 1,615 | 393 | 445 | 491 | N/A |
| 12/31/2021 | 1,580 | 386 | 404 | 492 | N/A |
| 9/30/2021 | 1,511 | 377 | 373 | 475 | N/A |
| 6/30/2021 | 1,460 | 365 | 303 | 413 | N/A |
| 3/31/2021 | 1,404 | 334 | 259 | 425 | N/A |
| 12/31/2020 | 1,449 | 355 | 272 | 404 | N/A |
| 9/30/2020 | 1,475 | 389 | -112 | 362 | N/A |
| 6/30/2020 | 1,499 | 391 | -84 | 388 | N/A |
| 3/31/2020 | 1,528 | 388 | -101 | 336 | N/A |
| 12/31/2019 | 1,482 | 369 | -125 | 319 | N/A |
| 9/30/2019 | 1,439 | 328 | 210 | 318 | N/A |
| 6/30/2019 | 1,399 | 322 | 202 | 301 | N/A |
| 3/31/2019 | 1,369 | 318 | 249 | 346 | N/A |
| 12/31/2018 | 1,352 | 312 | 273 | 358 | N/A |
| 9/30/2018 | 1,338 | 307 | 270 | 362 | N/A |
| 6/30/2018 | 1,333 | 306 | 210 | 307 | N/A |
| 3/31/2018 | 1,313 | 297 | -58 | 277 | N/A |
| 12/31/2017 | 1,288 | 289 | N/A | 273 | N/A |
| 9/30/2017 | 1,255 | 275 | N/A | 244 | N/A |
| 6/30/2017 | 1,217 | 262 | N/A | 286 | N/A |
| 3/31/2017 | 1,194 | 250 | N/A | 273 | N/A |
| 12/31/2016 | 1,154 | 237 | N/A | 255 | N/A |
| 9/30/2016 | 1,126 | 229 | N/A | 266 | N/A |
| 6/30/2016 | 1,096 | 218 | N/A | 261 | N/A |
| 3/31/2016 | 1,074 | 212 | N/A | 258 | N/A |
| 12/31/2015 | 1,048 | 199 | N/A | 247 | N/A |
| 9/30/2015 | 1,030 | 190 | N/A | 231 | N/A |
| 6/30/2015 | 1,019 | 181 | N/A | 217 | N/A |
| 3/31/2015 | 1,003 | 170 | N/A | 198 | N/A |
| 12/31/2014 | 987 | 161 | N/A | 179 | N/A |
| 9/30/2014 | 982 | 156 | N/A | 192 | N/A |
| 6/30/2014 | 972 | 146 | N/A | 167 | N/A |
| 3/31/2014 | 957 | 139 | N/A | 167 | N/A |
| 12/31/2013 | 942 | 134 | N/A | 171 | N/A |
| 9/30/2013 | 910 | 127 | N/A | 147 | N/A |
| 6/30/2013 | 886 | 126 | N/A | 150 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: RECDas prognostizierte Gewinnwachstum (10.4% pro Jahr) liegt über der Sparquote (2.3%).
Ertrag vs. Markt: RECDie Erträge des Unternehmens (10.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Italian (5.2% pro Jahr).
Hohe Wachstumserträge: RECDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: RECDie Einnahmen des Unternehmens (5.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Italian (3.9% pro Jahr).
Hohe Wachstumseinnahmen: RECDie Einnahmen des Unternehmens (5.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: RECDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (36.7%)